Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 926 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: PSORIASIS Clear all
Completed Phase 2 Interventional

A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis

NCT00540618
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
MEDI-507, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
36
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2007 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)

NCT03983980
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tapinarof, Vehicle Cream
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years to 75 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
42
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Fremont, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream

NCT05514353
View directory record Official record
Conditions
Healthy Volunteers, Psoriasis
Interventions
PBI-100 Topical Cream, Vehicle Cream
Drug
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 2 Interventional

Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

NCT00373516
View directory record Official record
Conditions
Psoriasis
Interventions
Vehicle (Placebo) applied BID, QRX-101 75 mcg/g ointment applied QD, QRX-101 75 mcg/g ointment applied BID
Drug
Lead sponsor
QuatRx Pharmaceuticals Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
12
States / cities
Hot Springs, Arkansas • Santa Rosa, California • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2006 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 2 Interventional

Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

NCT00287547
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
CTLA4Ig / Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
10
States / cities
San Diego, California • Chicago, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Nov 13, 2026, 2:03 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

NCT04908189
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Deucravacitinib, Placebo, Apremilast
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
24
States / cities
Mountain Brook, Alabama • Sacramento, California • Whittier, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

NCT05272150
View directory record Official record
Conditions
Plaque Psoriasis, Scalp Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
79
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 13, 2026, 2:03 PM EST
Recruiting Phase 4 Interventional

Multi-Center PAMPA Study

NCT05004727
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 13, 2026, 2:03 PM EST
Terminated Not applicable Interventional Results available

Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

NCT00477191
View directory record Official record
Conditions
Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity, Hypertension
Interventions
Etanercept
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 1Phase 2 Interventional Results available

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

NCT00585650
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept, Placebo injections
Biological · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Irvine, California • Winston-Salem, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 3 Interventional

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis

NCT00279162
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene/betamethasone gel and ointment
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Nov 13, 2026, 2:03 PM EST
Terminated Not applicable Interventional Results available

Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

NCT01094717
View directory record Official record
Conditions
Psoriasis
Interventions
Acitretin 25Mg Oral Capsule, Excimer laser, Tazarotene 0.1% Gel,Top, Sham excimer laser
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Nov 13, 2026, 2:03 PM EST
Completed No phase listed Observational

Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles

NCT00005781
View directory record Official record
Conditions
Dermatitis, Nevus, Psoriasis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326272
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 2 Interventional Results available

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

NCT02852967
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Belumosudil, Placebo
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
14
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis

NCT01206660
View directory record Official record
Conditions
Psoriasis
Interventions
Desoximetasone Spray 0.25%, placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hazleton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Nov 13, 2026, 2:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Conditioning, the Placebo Effect, and Psoriasis

NCT00005922
View directory record Official record
Conditions
Psoriasis
Interventions
Partial schedule of pharmacotherapeutic reinforcement, Dose control for Arm B, Standard pharmacotherapeutic protocol
Behavioral · Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
2
States / cities
Palo Alto, California • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 3 Interventional

Safety and Tolerability of Repeat Courses of IM Alefacept

NCT00233662
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Alefacept
Drug
Lead sponsor
Biogen
Industry
Eligibility
16 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Irvine, California • San Francisco, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Nov 13, 2026, 2:03 PM EST
Terminated No phase listed Observational

Predicting Medication Response for Autoimmune Disease

NCT04995783
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease, Psoriasis, Rheumatoid Arthritis
Interventions
Coral FRS test
Diagnostic Test
Lead sponsor
Coral Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 1Phase 2 Interventional

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

NCT00050648
View directory record Official record
Conditions
Psoriasis
Interventions
Daclizumab, Cyclosporine, cyclosporine and Daclizumab
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2009 · Synced Nov 13, 2026, 2:03 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Encinitas, California • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

Study of Secukinumab With 2 mL Pre-filled Syringes

NCT02748863
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, Secukinumab 2 mL form, Secukinumab 1 mL form
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Fountain Valley, California • Fremont, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

NCT01702493
View directory record Official record
Conditions
Psoriasis
Interventions
Cap SRT2104, Tab SRT2104 slow release, Tab SRT2104 intermediate release, Tab SRT2104 fast release, Selected formulations of SRT2104 from Part 1, Selected formulations of SRT2104 from Part 1 single alternative dose
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Nov 13, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

NCT04109976
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Boise, Idaho • Lexington, Kentucky • Baton Rouge, Louisiana + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Nov 13, 2026, 2:03 PM EST